Copyright
©The Author(s) 2024.
World J Gastroenterol. Feb 28, 2024; 30(8): 863-880
Published online Feb 28, 2024. doi: 10.3748/wjg.v30.i8.863
Published online Feb 28, 2024. doi: 10.3748/wjg.v30.i8.863
Figure 1 Example of a computed tomography image used for skeletal muscle measurements.
Figure 2 Survival curves for (A) progression-free survival and (B) overall survival in the presence or absence of sarcopenia.
PFS: Progression-free survival; OS: Overall survival.
Figure 3 Survival curves for (A) progression-free survival and (B) overall survival in the presence or absence of myosteatosis.
PFS: Progression-free survival; OS: Overall survival.
Figure 4 Survival curves for (A) progression-free survival and (B) overall survival in participants with gastric cancer in the presence or absence of sarcopenia.
PFS: Progression-free survival; OS: Overall survival.
Figure 5 Survival curves for (A) progression-free survival and (B) overall survival in participants with advanced gastric cancer in the presence or absence of myosteatosis.
PFS: Progression-free survival; OS: Overall survival.
Figure 6 Nomogram for progression-free survival.
A: Nomogram for progression-free survival (PFS); B: One-year and 3-year area under the curves for PFS; C: Calibration curves for PFS; D: Decision curve analysis for PFS. AUC: Area under the curve; PFS: Progression-free survival; OS: Overall survival; ALP: Alkaline phosphatase; Eosi: Eosinophil count; CA724: Carbohydrate antigen 724; CA125: Carbohydrate antigen 125.
Figure 7 Nomogram for overall survival.
A: Nomogram for overall survival (OS); B: One-year and 3-year area under the curves for OS; C: Calibration curves for OS; D: Decision curve analysis for OS. AUC: Area under the curve; OS: Overall survival; TP: Total protein; Eosi: Eosinophil count; CA724: Carbohydrate antigen 724; CA125: Carbohydrate antigen 125.
- Citation: Deng GM, Song HB, Du ZZ, Xue YW, Song HJ, Li YZ. Evaluating the influence of sarcopenia and myosteatosis on clinical outcomes in gastric cancer patients undergoing immune checkpoint inhibitor. World J Gastroenterol 2024; 30(8): 863-880
- URL: https://www.wjgnet.com/1007-9327/full/v30/i8/863.htm
- DOI: https://dx.doi.org/10.3748/wjg.v30.i8.863